Hengrui Medicine: HRS-4729 Injection Clinical Trial Approved

On September 4th, CSPC Pharmaceutical Group announced that the company and its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received the Approval Notice for Drug Clinical Trial of HRS-4729 Injection issued by the National Medical Products Administration. The company will conduct clinical trials soon. HRS-4729 Injection is a peptide drug independently developed by the company, which is a triple agonist of glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor/pancreatic glucagon-like peptide receptor. Compared to dual-target agonists GLP-1R/GIPR, the triple receptor agonist increases GCGR activation activity by regulating sugar and lipid metabolism and suppressing appetite in the body, promoting energy expenditure, fatty acid oxidation, lipid breakdown, and thus achieving better weight loss and reduction of liver fat effects.